Application of Kv3 in the preparation of products for diagnosing or treating abnormal fear memory extinction in post-traumatic stress disorder

By using Kv3.2 ion channels and PPP6C as therapeutic targets and employing a nanoliposome-coated siRNA strategy to regulate Kv3.2 phosphorylation levels, the treatment challenge of fading abnormal fear memories in PTSD was solved, achieving precise therapeutic effects and reducing side effects.

CN117448440BActive Publication Date: 2024-11-01FOURTH MILITARY MEDICAL UNIVERSITY
View PDF 2 Cites 0 Cited by

Patent Information

Application Number
CN202311375225.0
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2023-10-23
Publication Date
2024-11-01
Estimated Expiration
2043-10-23

AI Technical Summary

Technical Problem

Current technologies lack effective therapeutic targets for the extinction of abnormal fear memories in post-traumatic stress disorder (PTSD), especially since the specific molecular mechanisms of the thalamus in the process of fear memory extinction are unclear, making precise targeted intervention impossible.

Method used

Using the Kv3.2 ion channel as a molecular marker and therapeutic target, the phosphorylation level of Kv3.2 is regulated by negatively regulating PPP6C. The expression of PPP6C is precisely targeted and its activity is inhibited by a nanoliposome-coated siRNA (LNP-siRNA) strategy.

Benefits of technology

It provides precise therapeutic targets for the extinction of abnormal fear memories in post-traumatic stress disorder, reduces drug side effects and drug resistance, and promotes the extinction of fear memories.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN117448440B_ABST
    Figure CN117448440B_ABST
Patent Text Reader

Abstract

The present invention belongs to the field of biotechnology, and specifically relates to the use of Kv3 in the preparation of a product for diagnosing or treating abnormal fear memory extinction in post-traumatic stress disorder, providing a targeted therapeutic target for abnormal fear memory extinction in post-traumatic stress disorder.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention relates to the field of biotechnology, and in particular to application of Kv3 in preparing products for diagnosing or treating abnormal fear memory extinction in post-traumatic stress disorder. Background Art

[0002] Post-traumatic stress disorder (PTSD) refers to a mental illness that occurs after an individual suffers from abnormally strong mental stimulation. Abnormal fear memory extinction is a core symptom of PTSD patients, which seriously affects the patient's prognosis and daily life. At present, there is a lack of effective intervention methods in clinical practice. Previous studies believed that the thalamus is a relay station for sensory information. However, in recent years, a large number of studies have confirmed that the thalamus, especially the higher-order thalamus, is related to a variety of higher-level brain functions. This study found that the dorsomedial nucleus (MD) of the thalamus of PTSD model mice was overactivated during the extinction of fear memory, and optogenetic inhibition of this brain region can effectively promote the extinction of fear memory in PTSD mice. A large number of studies at home and abroad have mainly focused on brain regions such as the hippocampus, amygdala and prefrontal cortex, and more studies are conducted at the circuit level, and there are relatively few studies on the specific molecular level. As a hot topic in current research, the function of the thalamus in the extinction of fear memory has gradually been revealed. However, it is still unclear what specific thalamus is playing a role and through what pathways it participates in the extinction of fear memory.

[0003] Abnormal fear memory extinction is a core symptom that seriously troubles PTSD patients, and there is an urgent need to find targeted therapeutic targets in clinical practice. However, few effective intervention targets have been found. If the functional circuits involved and the abnormally changed molecules are not clearly identified, it is impossible to accurately target the protein level for intervention. Summary of the invention

[0004] In order to solve the above technical problems, the present invention provides the use of Kv3 in the preparation of a product for diagnosing or treating abnormal fear memory extinction in post-traumatic stress disorder.

[0005] Application of Kv3 in the preparation of products for diagnosing or treating abnormal fear memory extinction in post-traumatic stress disorder.

[0006] Preferably, the Kv3 is specifically Kv3.2.

[0007] Preferably, the phosphorylated Kv3.2 is used as a molecular marker for preparing a product for diagnosing abnormal fear memory extinction in post-traumatic stress disorder.

[0008] Preferably, when used as a molecular marker, the phosphorylation level of Kv3.2 is reduced.

[0009] Preferably, the Kv3.2 is used as a therapeutic target for preparing a product for treating abnormal fear memory extinction in post-traumatic stress disorder.

[0010] Preferably, the therapeutic target also includes PPP6C that interacts with Kv3.2.

[0011] Preferably, when PPP6C is negatively regulated, the phosphorylation level of Kv3.2 is upregulated.

[0012] Preferably, the nanoliposomes are coated with siRNA to negatively regulate PPP6C.

[0013] Preferably, the siRNA encapsulated by the nanoliposome takes effect in the MD brain region for 48 hours.

[0014] Preferably, the product for treating abnormal fear memory extinction in post-traumatic stress disorder negatively regulates PPP6C.

[0015] Compared with the prior art, the present invention has the following beneficial effects:

[0016] 1. The present invention proposes Kv3.2 ion channel as a molecular marker and therapeutic target, and also proposes PPP6C that interacts with Kv3.2 as a molecular marker and therapeutic target, providing a targeted therapeutic target for abnormal fear memory extinction in post-traumatic stress disorder.

[0017] 2. The LNP-siNRA strategy provided by the present invention can more accurately target the expression of PPP6C and avoid the side effects and drug resistance caused by drug treatment. BRIEF DESCRIPTION OF THE DRAWINGS

[0018] Figure 1 Schematic diagram of PTSD model construction and behavioral test diagram, A: PTSD model construction, B: Conditioned fear training on the 12th day, fear memory extinction experiment on the 14th day.

[0019] Figure 2 Conditioned fear behavior detection and Arc staining statistics, A: Fear memory extinction experiment results, B: Typical image of Arc staining during fear memory extinction, C: Statistical graph of Arc expression during fear memory extinction, ****P<0.0001.

[0020] Figure 3 Schematic diagram and statistical diagram of the patch clamp of the MD brain slice in vitro, A: Schematic diagram (upper) and actual picture (lower) of the MD patch clamp, B: Comparison of typical discharge diagrams between the PTSD model group and the control group, C: Typical diagram of the half-width comparison between the PTSD model group and the control group, D: Statistical diagram of the comparison of the number of discharges between the PTSD model group and the control group, E: Statistical diagram of the comparison of active and passive membrane properties between the PTSD model group and the control group, **P<0.01, ****P<0.0001;

[0021] Figure 4Statistical graphs of MD brain area optical fiber recordings, A: Typical graph of MD optical fiber recordings in the PTSD model group and the control group, B: Statistical graph of normalized peak values ​​in the PTSD model group and the control group, C: Heat map of MD optical fiber recordings during fear extinction in the PTSD model group and the control group, D: Curve graph of MD optical fiber recordings during fear extinction in the PTSD model group and the control group, **P<0.01;

[0022] Figure 5 The changes of Kv3 channel current in MD brain area, A: repeated results of Kv3 current in MD brain area of ​​control group, B: repeated results of Kv3 current in MD brain area of ​​PTSD model group, C: statistical graph of Kv3 current peak value in MD brain area of ​​PTSD model group and control group and schematic diagram of experimental method, D: statistical graph of mean Kv3 current in MD brain area of ​​PTSD model group and control group, ****P<0.0001;

[0023] Figure 6 The expression differences of Kv3 family in MD brain regions, A: Kcnc1 RNA expression map in MD brain regions, B: Kcnc2 RNA expression map in MD brain regions, C: Kcnc3 RNA expression map in MD brain regions, D: Kcnc4 RNA expression map in MD brain regions;

[0024] Figure 7 The expression levels of Kv3.1 and Kv3.2 proteins in the MD brain region, A: Typical graph of Kv3.1 and Kv3.2 protein expression in the MD brain region of the PTSD model group and the control group, B: Statistical graph of Kv3.1 protein levels in the MD brain region of the PTSD model group and the control group, C: Statistical graph of Kv3.2 protein levels in the MD brain region of the PTSD model group and the control group;

[0025] Figure 8 The phosphorylation levels of Kv3.1 and Kv3.2 proteins in the MD brain region, A: Statistical graph of Kv3.1 protein phosphorylation in the MD brain region of the PTSD model group and the control group, B: Statistical graph of Kv3.2 protein phosphorylation in the MD brain region of the PTSD model group and the control group, ***P<0.001;

[0026] Fig. 9 Mass spectrometry analysis of MD brain regions;

[0027] Fig.10 is the interaction level between CSNK2B and PPP6C and Kv3.2, A: Typical expression diagram of CSNK2B and PPP6C proteins in MD brain region of PTSD model group and control group, B: Statistical diagram of CSNK2B protein expression in MD brain region of PTSD model group and control group, C: Statistical diagram of PPP6C protein expression in MD brain region of PTSD model group and control group, **P<0.01;

[0028] Fig.11The designed siPPP6C sequences and in vitro knockout effect diagram, A: 4 designed siPPP6C, B: mRNA level verification statistics after in vitro knockout of 4 sequences, ****P<0.0001;

[0029] Fig.12 Schematic diagram of LNP-coated siPPP6C and administration method, A: Schematic diagram of the structure of LNP-coated siPPP6C, B: Molecular structure of the material used for LNP coating, C: Schematic diagram of the in vivo effect of LNP, D: Schematic diagram of LNP administration method;

[0030] Fig.13 The expression level of PPP6C and the phosphorylation level of Kv3.2 after conditional knockdown of PPP6C by siRNA, A: Typical graph of PPP6C protein expression level in MD brain region 24h, 48h, and 72h after administration of siPPP6C, B: Statistical graph of PPP6C protein expression level in MD brain region 24h, 48h, and 72h after administration of siPPP6C, C: Typical graph of Kv3.2 phosphorylation level in MD brain region of siPPP6C group and siCon group, D: Statistical graph of Kv3.2 phosphorylation level in MD brain region of siPPP6C group and siCon group, **P<0.01, ***P<0.001;

[0031] Fig.14 The changes of Kv3 current in MD brain region after conditional knockdown of PPP6C by siRNA, A: Kv3 current in MD brain region of LNP-empty group, B: Kv3 current in MD brain region of LNP-siRNA group, C: Statistical graph of Kv3 current peak value in MD brain region of LNP-empty group and LNP-siRNA group, D: Statistical graph of Kv3 current mean value in MD brain region of LNP-empty group and LNP-siRNA group, ****P<0.0001;

[0032] Fig.15 The electrophysiological changes in the MD brain after conditional knockdown of PPP6C by siRNA, A: Schematic diagram of administering LNP-siPPP6C to the MD brain and performing patch clamp, B: Statistical graph of neuronal discharges in the MD brain in the siRNA group and the control group, C: Typical graph of the half-width of neurons in the MD brain in the siRNA group and the control group, D: Statistical graph of active and passive membrane properties of neurons in the MD brain in the siRNA group and the control group, ****P<0.0001;

[0033] Fig.16 The behavioral phenotypes of mice after conditional knockdown of PPP6C by siRNA, A: Schematic diagram of surgery and behavioral testing in the PTSD model group and the control group, B and C: Statistical graphs of fear memory extinction in the PTSD model group and the control group, D: Statistical graph of fear extinction memory in the PTSD model group and the control group, ****P<0.0001; DETAILED DESCRIPTION

[0034] The specific embodiments of the present invention are described in detail below, but it should be understood that the protection scope of the present invention is not limited by the specific embodiments. Based on the embodiments of the present invention, all other embodiments obtained by ordinary technicians in this field without creative work belong to the protection scope of the present invention. The experimental methods described in the embodiments of the present invention are conventional methods unless otherwise specified.

[0035] In the examples of the present invention, the mouse stereotaxic instrument was purchased from Shenzhen Ruiwode Company, the glass microsyringe was purchased from Hamilton Company in Switzerland, and a Leica cryostat, an Olympus digital slice scanner VS200 and a laser confocal microscope FV 3000 were used. The viruses used were purchased from Wuhan Brinkase Biotechnology Co., Ltd. Optogenetics and fiber optic recording equipment were purchased from Qianao Xingke Nanjing Biotechnology Co., Ltd.

[0036] In the embodiments of the present invention, the materials used include: PPP6C siRNA (siPPP6C-4), LNP-siPPP6C (LNP-siRNA).

[0037] In the embodiment of the present invention, the specific experimental steps are as follows:

[0038] (1) SPS&S model construction

[0039] First, C57 mice were placed in a restraint device and then placed in a mouse cage for 4 hours. After an interval of 30 minutes, the mice were placed in a transparent bucket filled with water for forced swimming for 20 minutes. The diameter of the transparent bucket was 20 cm, the height was 30 cm, the water level in the bucket was 20 cm, and the water temperature was 25°C. After an interval of 30 minutes, the mice were deeply anesthetized with ether until the mice lost their reaction to pinching the tail and toes. After an interval of 30 minutes, unconditional plantar electrical stimulation was applied in a box with an electric shock device. The box size was 25 cm x 25 cm x 25 cm, and the electrical stimulation conditions were 0.8 mA, 5 s. The mice in the control group were placed in the box but no stimulation was applied.

[0040] For methods to determine whether the model is successful, refer to the article Xi K, Huang X, Liu T, Liu Y, Mao H, Wang M, et al. Translational relevance of behavioral, neural, and electroencephalographic profiles in a mouse model of post-traumatic stress disorder. Neurobiol Stress. 2021; 15: 100391. doi: 10.1016 / j.ynstr.2021.100391.

[0041] (2) Stereotaxic brain injection

[0042] The mice were anesthetized with isoflurane and fixed on a stereotaxic instrument. The anesthesia was induced at 2.5% and maintained at 1.5%. The oxygen flow rate was 1L / min. The skull was exposed by shaving. The surgical area of ​​the skull was routinely disinfected with iodine. Erythromycin ointment was applied to the eye surface to protect the eyeballs of the animals. After the disinfectant dried, a 1.5-2.0 cm long longitudinal skin incision was made along the midline of the skull with ophthalmic scissors. The subcutaneous tissue was bluntly separated to fully expose the anterior and posterior bregmas of the mice. The leveling instrument was adjusted, and a micro-skull drill was used to make holes. Under a stereo microscope, micro-tweezers were used to carefully tear off the dura mater in the hole area and expose the pia mater. The micro-injector was slowly adjusted, and the virus solution was injected with a glass micro-tube syringe. The MD was positioned: anterior to the anterior bregma: -1.70 mm, left of the suture: +0.30 mm, and depth under the skull: -3.40 mm. After intracranial injection, the needle was retained for at least 10 min before being slowly withdrawn to allow the virus to be fully absorbed by the tissue. After the intracranial injection, the surgical area was disinfected again with iodine, the incision epidermis was sutured, and antibiotic ointment was applied around the incision to prevent infection. 2 mg / kg of meloxicam was injected intraperitoneally as an analgesic, and the patient was kept warm on an electric blanket until awakening. Subsequent experiments were conducted 3 weeks after the virus was expressed.

[0043] (3) Brain extraction by perfusion

[0044] After isoflurane anesthesia, the animal was fixed in a supine position, the abdominal wall below the sternum was cut open, the thorax was lifted to fully expose the heart, the right atrial appendage was cut open, and 0.1% phosphate buffer (PBS) was dripped. After the buffer flowing out of the right atrial appendage was clarified, a phosphate buffer containing 4% paraformaldehyde was changed to drip for about 15 minutes, and the phosphate buffer containing 4% paraformaldehyde was used as the fixative. After the end, the brain was taken out, placed in the same fixative and fixed for 4 hours, and then the brain was placed in a phosphate buffer containing 10%, 20%, and 30% sucrose for gradient dehydration until the brain tissue sank to the bottom.

[0045] (4) Frozen sections

[0046] The dehydrated brain tissue was quickly frozen in a slicer using OCT embedding medium, fixed on the platform of the freezing slicer, flattened to the level of the coronal plane, sliced ​​to a thickness of 50 μm, and then stored in 0.1% phosphate buffer solution in the order of slicing.

[0047] (5) Immunofluorescence staining

[0048] The brain sections were washed 3 times with 0.1% PBS on a shaker for 10 minutes each time, and then blocked with blocking solution. After 2 hours, primary antibody staining was performed, and the sections were kept at 4° overnight. After 18 hours, the brain sections were washed 3 times with 0.1% PBS on a shaker for 10 minutes each time, and then secondary antibody staining was performed. After 3 hours, the brain sections were washed 3 times with 0.1% PBS on a shaker for 10 minutes each time. Then DAPI staining was performed, and the sections were mounted and sealed and stored away from light.

[0049] (6) Patch clamp of isolated brain slices

[0050] After the mouse was anesthetized with isoflurane, the brain was removed by decapitation. The skin of the head was cut open to expose the skull. The skull was cut open along the left side and opened to the right to fully expose the brain tissue. The brain tissue of the mouse was quickly removed with a brain spoon and placed in a slice solution mixed with ice and water. The slice solution should be pre-oxygenated, and the oxygen composition is 95% O2 + 5% CO2. The removed brain tissue was slightly trimmed, and the mouse brain was fixed on the platform of the oscillating slicer with glue. The slicer slot should be pre-placed with a mixture of ice and water, and the mixed gas was introduced at the same time. Coronal slices were made with a slice thickness of 300μm. The cut brain slices were placed in a fully oxygenated slice solution and incubated at 32℃ for 30min. After that, the slice solution was replaced with artificial cerebrospinal fluid and incubated for another 1h. After the incubation, the brain slices were placed in the bath of the microscope platform, fixed with a U-shaped cover net, and the artificial cerebrospinal fluid was continuously perfused with oxygen. MD was found under the microscope. The glass electrode is filled with electrode internal liquid, and the internal liquid of the motor is K-Glu. The air bubbles are exhausted by tapping with fingers. A certain positive pressure is applied before entering the liquid to prevent impurities in the perfusion fluid from clogging the tip of the glass electrode. The tip of the glass electrode is attached to the neuron using a micromanipulation system. While releasing the positive pressure, negative pressure is applied to attract the neuron. After a high-resistance seal is formed, negative pressure is applied with the mouth to break the membrane. Recording is performed using an Axonclamp-200B / 700B amplifier.

[0051] (7) Fiber Optic Recording

[0052] 2-3 weeks after virus injection and fiber implantation, mice were connected to the recording device and the presence of fluorescent signals was confirmed. Before each recording, the implanted fiber was connected to the recording device via an external optical fiber, China. To excite GCaMP6s, a 473 nm light-emitting diode (LED) was reflected by a dichroic mirror focused with a 0.4 numerical aperture (NA) 20x objective lens and coupled to an optical redirector (Doris lens). The optical fiber guided the light between the redirector and the implanted fiber, and the optical density of the fiber was 230 μm, 0.37 NA. The laser power at the fiber tip was adjusted to 0.01-0.02 mW to reduce laser bleaching. The fluorescence was bandpass filtered, and an amplifier was used to convert the CMOS (complementary metal oxide semiconductor) current output into a signal, which was further filtered by a low-pass filter with a 40 Hz cutoff. The analog voltage signal was digitized at a frequency of 50 Hz and recorded by a multi-channel fiber optic photometry recording system. Among them, the brand of the recording device is Qianao Xingke, the brand of the 20x objective lens is Olympus, the brand of the dichroic mirror is MD498, Thorlabs, the brand of the bandpass filter is MF525-39, Thorlabs, and the brand of the CMOS is DCC3240M, Thorlabs).

[0053] (8) Optogenetics

[0054] The wireless optogenetic device integrates various functional layers, barrier membranes, and active elements fabricated on a 75 μm thick polyimide substrate in an overall planar geometry that facilitates processing with conventional manufacturing techniques. The functional layers are copper metallization, the barrier membranes are perylene and polydimethylsiloxane, and the active elements are surface mounted chips and μILEDs. The electrical interface consists of a pair of metal wires along a snake-like interconnect trace that allows vertical and horizontal freedom of movement relative to the connected circular coil. The surface mounted chip, circular coil diameter 9.8 mm, copper traces: 8 turns, 60 μm wide, 18 μm thick, 80 μm spacing, transmits power and control to an independent RF transmission loop antenna operating at 13.56 MHz via magnetic coupling. A 23 pF capacitor provides impedance matching. The diode rectifies the received RF signal to generate the current source for the μ-ILEDs. In the experiment of optogenetic neuronal activity manipulation, the eNpHR 3.0 was activated with a 589 nm laser with a 5 mW constant yellow light.

[0055] (9) Western Blotting

[0056] ① The protein sample was taken out of the -80℃ refrigerator and placed on ice. After thawing, it was centrifuged at 4℃, 12000rpm for 10 minutes to obtain the supernatant. 5× protein loading buffer was added to prepare the sample. Meanwhile, the gel was prepared according to the instruction manual of TGX Stain-FreeFastCastAcrylamide Kit, 10% (cat.#161-1083). 1×RunningBuffer was prepared, and each L of the electrophoresis buffer contained 25mM Tris, 192mM Glycine and 0.1% SDS, and mixed well.

[0057] ② Rinse the electrophoresis tank and rack used for running gel repeatedly with clean water, assemble the equipment with the glass plate with gel, and pay attention to the close connection between the glass plate and the rack of the gel, which is the key step to prevent leakage during electrophoresis; slowly pour the well-mixed 1× Running Buffer electrophoresis liquid into the electrophoresis tank, and do not pour the electrophoresis liquid rich in bubbles into the tank between the middle glass plates;

[0058] ③ Add the heated protein samples to the gel glass plate in sequence. After the addition is completed, the samples are immediately returned to the refrigerator for storage. During the addition process, the pipette tip must be inserted vertically from the top middle of the well, and the sample is slowly added from the bottom of the well. As the sample is continuously added to the well, the pipette tip must be continuously lifted up to always keep the pipette tip above the liquid level of the sample just added, so as to avoid some bubbles generated when the sample is discharged at the end, which will bring the added protein sample out of the well just added.

[0059] ④ Record the order of sample loading, load the protein marker according to the order of protein loading and the molecular weight of the protein, plug in the power supply, first run the protein to the separation gel at a constant voltage of 80V for about 30 minutes, then run the gel at a constant voltage of 120V for about 50 minutes, until the bromofen blue indicator solution in the loading buffer reaches the edge of the bottom gel, stop running the gel;

[0060] ⑤ Use clean water to repeatedly clean all the equipment to be used, including: the rack used for transfer, electrophoresis tank, green film, white filter paper and black sponge, etc.; soak the white filter paper and black sponge in different clean water for later use;

[0061] ⑥ Prepare electrophoresis transfer buffer. 1L needs to add 200mL methanol and 100mL 10×Tris / GlycineBuffer, and then add water to 1L. The added water should be pre-cooled in advance. Soak the cut PVDF membrane in methanol for about 5 minutes, and then transfer it to the newly prepared transfer buffer for soaking.

[0062] ⑦ Place the rack to be transferred in a large amount of clean water, open it and arrange it so that the black part is at the bottom, then place a black sponge, two white filter papers and the soaked PVDF membrane in sequence, and use flat-tipped tweezers to take it when placing it;

[0063] ⑧Use the prepared gel prying device to gently remove the gel, and use the green film remover to cut off the excess part so that the gel can be flattened. First place the gel in the transfer buffer, and then transfer it to the PVDF membrane prepared in the previous step; then place a white filter paper and a black sponge on the PVDF membrane in turn. Be careful not to generate bubbles during the entire experiment. Note that you should try to use new filter paper. If the filter paper is used too many times, some debris will be generated, which will affect the effect of the transfer, so be sure to wash and soak the filter paper used with clean water first. If some obvious debris is generated, you need to discard it and replace it with a new filter paper.

[0064] ⑨ Use a clean roller to gently roll the placed transfer system to drive out the bubbles that may exist in the transfer system, then slowly close the rack and buckle it, take out the transfer system from the clean water, and after the excess clean water is drained, transfer it to the transfer buffer and soak it, waiting for the installation of the next gel. Then put the two transfer racks together into the transfer electrophoresis tank with the transfer solution, with the white side of the transfer rack facing the red side of the transfer electrophoresis tank, and the black side facing the black side, pour enough transfer buffer to fill the entire transfer electrophoresis tank, and add an ice box that has been pre-chilled at -20℃, then plug in the power supply, bury the entire electrophoresis tank in the ice-water mixture, and choose the transfer time according to the molecular weight.

[0065] ⑩After the transfer, transfer to 5% skim milk powder for blocking for 1 hour, rinse twice in TBST buffer, remove TBST buffer, add the first antibody diluent according to the dilution multiple in the product instructions, shake gently on a shaker in a 4°C refrigerator, recover the first antibody diluent the next day, rinse three times with TBST buffer, 10 minutes each time, then add the second antibody diluent of the same properties, incubate at room temperature for 2 hours, and then rinse three times with TBST buffer, 15 minutes each time. Expose and develop with a developer and perform quantitative analysis on the images.

[0066] (10) Co-immunoprecipitation (co-IP)

[0067] ① For each treatment group of cells collected, lyse the cells on ice with freshly prepared lysis buffer. Before use, add 25×Complete inhibitor, 10×PhosphoStop inhibitor and 100×PMSF to the lysis buffer. Add 800μL IP lysis buffer to each tube of cells. During the addition process, use a pipette to repeatedly pipette up and down to fully sprinkle the cells. Place them on a 4℃ shaker for lysis for 4 hours; centrifuge at 4℃ at 12000rpm for 15 minutes. After centrifugation, transfer the supernatant to a new EP tube for pre-clearing;

[0068] ②First take a total of about 150μL*4 magnetic beads, wash them once with a lysis buffer without inhibitors, then resuspend the magnetic beads with 150μL*4 lysis buffer, and then add 20μL of magnetic beads to each of the 12 EP tubes containing proteins for pre-clearing treatment. Before using a 200μL yellow pipette tip, you need to cut off a small section with scissors to avoid damaging the magnetic beads, and rotate at 4℃ for one hour; at the same time, take 90μL*4 magnetic beads and add 12μL*4 flag M2 antibodies to form a magnetic bead-antibody complex and rotate at 4℃ for one hour;

[0069] ③ Take the EP tube containing protein after pre-clearing and place it on the magnetic rack, gently pipette the supernatant into a new EP tube, rinse with magnetic bead lysis buffer, then add 100 μL PBS to resuspend and store at 4°C. PBS contains 0.5% NaN3.

[0070] ④ After pre-clearing, there are 12 tubes of supernatant protein solution. Take out 80μL from each tube as input. Take out 55μL from the remaining 720μL of supernatant and mix them together to make a total of 660μL as IgG control;

[0071] ⑤ Add 32 μL of the above-treated magnetic bead-antibody complex to the remaining 665 μL of the supernatant protein solution in 12 tubes respectively, and add all the above-mentioned magnetic bead-IgG complexes to the IgG control group, and rotate at 4°C for 2 hours;

[0072] ⑥ Place the above 12 EP tubes and the EP tube of the IgG control group on the magnetic rack, gently aspirate the supernatant for elution, and then wash the magnetic beads with 1mL lysis buffer for 15 minutes*3, rotating at 4℃, discarding the supernatant after each wash; wash the magnetic beads with PBS for 2 minutes*5, using 1mL PBS each time, rotating at 4℃, retaining the magnetic beads, and resuspending with 1mL PBS for the last time, take 200μL from each tube and divide it into one tube, 800μL from one tube, place it on the magnetic rack to absorb PBS, and add 50μL 1*loading after the EP tube containing 200μL magnetic beads is dried, and the EP tube containing 800μL magnetic beads is dried and placed in a -80℃ refrigerator for sample delivery and testing;

[0073] ⑦Input and elution were added 26.7μL, 192μL4*loading respectively;

[0074] ⑧Perform the same experimental steps as Western Blotting.

[0075] Example 1

[0076] Behavioral experiments

[0077] First, the SPS&S method was used to construct a PTSD mouse model. Figure 1 As shown in A, including restraint, forced swimming, deep anesthesia and unconditional plantar electrical stimulation, a control group and a PTSD model group were set up. The control group was untreated wild-type mice, and then the conditioned fear behavior experiment was tested ( Figure 1 B).

[0078] On the first day, mice were placed in environment A for training. First, the mice were allowed to adapt for 2 minutes, and then given 30 seconds of continuous sound stimulation, and 0.8 mA of foot electrical stimulation was given in the last 2 seconds, and then rested for 1 minute, and 10 cycles were performed in sequence. 48 hours later, on the third day, the mice were placed in environment B, adapted for 2 minutes, and then given 30 seconds of continuous sound stimulation, and then rested for 1 minute, and 30 cycles were performed in this way to detect the extinction of the fear memory learned by the mice on the first day. 24 hours later (the fourth day), the mice were placed in environment B, adapted for 2 minutes, and then given 30 seconds of continuous sound stimulation, and then rested for 1 minute, and 5 cycles were performed in this way to detect the extinction level of the fear memory of the mice, wherein the sound stimulation conditions were 75 dB, 4500 Hz.

[0079] Environment A: a 25cm*25cm*25cm square box with a sound-generating device and an electric shock device inside; Environment B: a transparent barrel with a diameter of 20cm and a height of 30cm.

[0080] The results showed that the PTSD model mice maintained a high freezing level during the fear extinction behavior on the third day, indicating that the mice continued to be afraid, while the freezing level of the control group mice gradually decreased with the increase in the number of experiments, suggesting that the fear extinction of PTSD mice was abnormal. Figure 2 A.

[0081] Example 2

[0082] Voltage-gated potassium channel Kv3.2 affects neurons in the MD brain region

[0083] Immunofluorescence staining revealed that the expression of Arc, an immediate response gene (IEG) protein in the MD brain region, was significantly increased in PTSD mice. Figure 2 B and Figure 2C, indicating that the activity of the MD brain area is enhanced. At the same time, the electrophysiological characteristics of neurons in the MD brain area were detected using the in vitro brain slice patch clamp technique, and it was found that the neuronal discharge of PTSD mice was significantly higher than that of the control group, such as Figure 3 A. Figure 3 B and Figure 3 D, the half width of the neuron is significantly lower than that of the control group. Figure 3 C and Figure 3 E. Furthermore, the optical fiber recording method was used to record the activity changes of neurons in the MD brain region during the extinction of fear memory, and it was found that the calcium activity in the MD brain region of PTSD mice was significantly higher than that of the control group during the extinction of fear memory. Figure 4 A and Figure 4 B. As the number of experiments increased, the peak value of calcium signal in the MD brain region of PTSD mice continued to remain at a high level, while that of the control group mice gradually decreased. Figure 4 C and Figure 4 D.

[0084] Previous literature reports that voltage-gated potassium channel Kv3 is involved in the repolarization process of fast-discharging neurons. Therefore, it is speculated that the reduction in the half-width of neurons in the MD brain region may be due to changes in Kv3 channels. The Kv3 current in the MD brain region was recorded using the in vitro brain slice patch clamp technique, and it was found that the Kv3 current intensity of PTSD mice was significantly higher than that of the control group, such as Figure 5 AD. The Kv3 family includes Kv3.1, Kv3.2, Kv3.3, and Kv3.4. In addition, it was found that only Kv3.1 and Kv3.2 were expressed in the MD brain region, such as Figure 6 Therefore, we then used Western blotting (WB) to detect the protein levels of Kv3.1 and Kv3.2 in the MD brain region and found no significant differences. Figure 7 AC.

[0085] Considering that phosphorylation modification may affect protein activity, the phosphorylation levels of the two molecules were then detected using co-immunoprecipitation (Co-IP) technology, and it was found that the phosphorylation level of Kv3.2 was significantly reduced, such as Figure 8 C and Figure 8 D, while there was no significant change in the phosphorylation level of Kv3.1. Figure 8 A and Figure 8 B, suggesting that Kv3.2 may play an important role.

[0086] Example 3

[0087] PPP6C affects the phosphorylation of Kv3.2, leading to abnormal fear memory extinction

[0088] Mass spectrometry analysis of MD brain regions revealed two molecules that interact with Kv3.2, namely CSNK2B and PPP6C. Fig. 9, and found that the expression levels of both molecules were significantly increased, such as Fig.10 AC. CSNK2B is a phosphorylase, while PPP6C is responsible for dephosphorylating the target protein. Considering the reduced phosphorylation level of Kv3.2, it is speculated that PPP6C may play a more important role. Subsequently, four small interfering RNAs (siRNAs) were designed to conditionally knock out PPP6C, such as Fig.11 A. The results of in vitro experiments suggested that siPPP6C-4 had a better effect, so this sequence was used in subsequent experiments, such as Fig.11 B.

[0089] Considering the instability of siRNA administration in vivo, a new delivery technology, nanoliposome-encapsulated siRNA (LNP-siRNA), was used. Fig.12 A and Fig.12 B, thereby improving the transfection efficiency of siRNA and avoiding metabolism by the body, such as Fig.12 C and Fig.12 D.

[0090] First, the drug was administered at different time periods, i.e., 24 hours, 48 ​​hours, and 72 hours, to determine the optimal time for the experiment.

[0091] WB results suggested that after stereotaxic administration of LNP-siRNA to the MD brain region for 48 h, the knockdown effect of PPP6C was better, e.g. Fig.13 A and B, and the phosphorylation level of Kv3.2 was also significantly upregulated, such as Fig.13 C and Fig.13 D, therefore, subsequent behavioral and in vitro electrophysiological experiments all used a 48-hour time window.

[0092] The in vitro electrophysiological results showed that the Kv3 current in the MD brain area was significantly reduced after LNP-siRNA administration ( Fig.14 AD, and the half-width of MD neurons also increased significantly, such as Fig.15 AD, further confirming the important role of PPP6C.

[0093] Finally, behavioral tests were conducted, such as Fig.16 A, It was found that after LNP-siRNA conditionally knocked down PPP6C in the MD brain region, the freezing level of PTSD mice during fear extinction on the third day was significantly reduced, as shown in Fig.16 B and Fig.16 C, indicating that the fear memory of mice gradually faded. Similarly, we also observed that the freezing level of PTSD mice was significantly reduced after conditional knockdown of PPP6C in the MD brain region during the fear recall process on the 4th day. Fig.16 D.

[0094] It should be noted that when the claims of the present invention involve numerical ranges, it should be understood that the two endpoints of each numerical range and any numerical value between the two endpoints can be selected. In order to avoid redundancy, the present invention describes a preferred embodiment.

[0095] Although the preferred embodiments of the present invention have been described, those skilled in the art may make other changes and modifications to these embodiments once they have learned the basic creative concept. Therefore, the appended claims are intended to be interpreted as including the preferred embodiments and all changes and modifications that fall within the scope of the present invention.

[0096] Obviously, those skilled in the art can make various changes and modifications to the present invention without departing from the spirit and scope of the present invention. Thus, if these modifications and variations of the present invention fall within the scope of the claims of the present invention and their equivalents, the present invention is also intended to include these modifications and variations.

Claims

1. Use of nanoliposome-encapsulated siRNA in the preparation of a drug for treating abnormal fear memory extinction in post-traumatic stress disorder, wherein the siRNA is Ppp6c-Mus-827; The sequences of the sense strand and antisense strand of Ppp6c-Mus-827 are CACGAAGGCUAUAAGUUUATT and UAAACUUAUAGCCUUCGUGTT, respectively.

2. The use according to claim 1, characterized in that: Nanoliposome-encapsulated siRNA negatively regulates PPP6C.

3. The use according to claim 2, characterized in that: The nanoliposome-encapsulated siRNA takes effect in the MD brain region 48 hours after administration.

Citation Information

Patent Citations

  • Kv3 modulators

    CN115066424A

  • Hydantoin derivatives useful as KV3 inhibitors

    WO2013083994A1